Lipa Pharmaceuticals is an Australian integrated manufacturer of dietary supplements and over-the-counter pharmaceutical products. It manufactures tablets, soft gelatine capsules, two-piece hard gelatine capsules, powders, liquids and creams.
Lipa Pharmaceuticals will be responsible for obtaining the appropriate regulatory approvals from the Australian Therapeutic Goods Administration, while providing logistic and sales support.
Qualitas’s Almega PL is a vegetarian EPA-rich, polar lipid-structured omega-3 oil. Sourced from Nannochloropsis oculata, a non-GMO strain of microalgae selected for its high level of EPA omega-3 and unique polar-lipid structure, it contains omega-3 fatty acids with phospholipids and glycolipids that provide superior absorption and digestibility.
Farmed from microalgae are a source of omega-3s that do not deplete the marine ecosystem, Almega PL is sustainably produced using natural sunlight, non-arable land and low-energy processes.
“This agreement extends our Almega PL sales efforts to a large, vibrant and growing omega-3 market which is increasingly demanding a vegetarian and sustainable alternative” said Yuri Shoshan, chief executive of Qualitas Health.
“We see great potential for Almega PL in Australia,” said Dusko Pejnovic, chief exeutive at Lipa Pharmaceuticals.
“The improved bioavailability from the polar lipids is an essential benefit, as Australia has a well-established krill oil market and consumers are aware of the importance of bioavailability.”